The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.00
Bid: 308.00
Ask: 308.50
Change: 14.50 (4.97%)
Spread: 0.50 (0.162%)
Open: 298.00
High: 308.00
Low: 285.50
Prev. Close: 291.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading and COVID-19 Update

29 Apr 2020 07:00

RNS Number : 2338L
Synthomer PLC
29 April 2020
 

29th April 2020

 

Synthomer plc

Q1 Trading and COVID-19 Update

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2020.

Q1 Trading

As announced previously, the Group has experienced a solid start to the year with EBITDA approximately 5% ahead of the comparative Q1 period for the heritage business, and in line with expectations set out at the time of Synthomer's full year results announcement.

Performance Elastomers

Our Nitrile Butadiene Latex ('Nitrile') business continued to benefit from the additional 90kt of capacity introduced in Q4 2018 at our Pasir Gudang site. We saw higher volumes due to COVID-19, although unit margins were marginally lower relative to a strong comparative period in 2019. Styrene Butadiene Rubber ('SBR') market conditions stabilised with volumes in line and unit margins ahead of prior year. The strategic review of our European SBR network is ongoing and a further update will be provided in due course.

Functional Solutions

Whilst reported volumes were lower than the comparative period this was compensated for by stronger unit margins as a result of improved mix and softer raw material markets. Progress has been supported by the expansion of our Worms, Germany and Roebuck, USA dispersions facilities last year which introduced low cost capacity to drive organic growth in differentiated applications.

Industrial Specialities

Performance has continued in line with expectations. Excluding the impact of our acrylate monomer business, which largely supplies internal demand, all businesses made progress with volumes in line and margins ahead of the comparative period in 2019.

COVID-19 Update

The Group continues to operate 37 of its 38 global manufacturing sites, with speciality chemicals designated as key industrial assets in the geographies in which Synthomer operates. To date, the Group has experienced no significant issues with regards to raw material supply, the distribution of finished goods or the availability of operating personnel.

Notwithstanding Synthomer's broad geographic and end market diversity, Q2 sales into industrial markets including Automotive and the Oil & Gas sector are currently being impacted. However demand for Nitrile continues to be strong particularly as a result of the COVID-19 pandemic.

 

As previously announced, the Group has a strong balance sheet with significant leverage covenant headroom (4.25x and 4.00x EBITDA for 2020 and 2021), and significant liquidity underpinned by the 2024 committed unsecured 5 year €460m RCF and $260m term loan bank facilities.  

 

Synthomer expects to reduce its capital expenditure for 2020 to approximately £50m from the £73.5m originally anticipated (including OMNOVA). The Group has recently completed a material capital expenditure programme and its asset base remains well invested.

Under the current circumstances, the Group's Board, Executive and Senior Management have frozen their salaries at 2019 levels and delayed any further review until October 2020.

Following the completion of the OMNOVA transaction, as announced on the 1st April 2020, the ongoing integration of the business is progressing. We confirm delivery of the expected $29.6m synergy is on track. OMNOVA reported EBITDA Q1 2020 marginally ahead of Q1 2019 but given their exposure to a broad range of industrial markets expect an impact from the COVID-19 pandemic in the months ahead.

Outlook

Given the unprecedented uncertainty around the impact of COVID-19, it is unclear what impact this will have on the Group's financial performance for the year. As such, the Group is withdrawing its previous guidance for the year ending 31st December 2020 and will update the market when there is better visibility.

Over the medium term the Board remains confident that Synthomer is well positioned due to the Group's strong geographic and end market diversity combined with self-help initiatives and the future benefits to come from the successful acquisition and integration of OMNOVA.

-ENDS-

 

Enquiries:

 

Synthomer plc

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, President, Corporate Development

Tel: + 44 7764 859147

 

 

Teneo

Charles Armitstead / Matt Denham

Tel: + 44 7703 330 269

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEUFAAESSEEL
Date   Source Headline
1st Jul 20167:00 amRNSCompletion of acquisition and trading update
31st May 201611:31 amRNSAudit Tender
16th May 20164:17 pmRNSHolding(s) in Company
9th May 201612:31 pmRNSDirector/PDMR Shareholding
28th Apr 20163:11 pmRNSResult of AGM
28th Apr 20167:00 amRNSQ1 Trading update
21st Apr 20161:44 pmRNSHolding(s) in Company
20th Apr 20162:23 pmRNSDirector Declaration
11th Apr 20163:01 pmRNSDirector/PDMR Shareholding
11th Apr 20163:00 pmRNSDirector/PDMR Shareholding
31st Mar 20162:15 pmRNSAnnual Financial Report
21st Mar 20167:00 amRNSAcquisition
21st Mar 20167:00 amRNSDisposal
15th Mar 201612:29 pmRNSHolding(s) in Company
2nd Mar 20167:00 amRNSPreliminary Results for the year ended 31 Dec 2015
10th Feb 20167:00 amRNSFRS 101 Notification
5th Feb 20163:34 pmRNSHolding(s) in Company
5th Feb 20163:13 pmRNSHolding(s) in Company
30th Nov 20153:00 pmRNSHolding(s) in Company
18th Nov 201510:30 amRNSDirector/PDMR Shareholding
6th Nov 20157:00 amRNSQ3 Trading Update
1st Oct 201512:50 pmRNSHolding(s) in Company
13th Aug 201510:05 amRNSHolding(s) in Company
11th Aug 20157:00 amRNSHalf Yearly Results
10th Jul 20152:43 pmRNSDirector/PDMR Shareholding
9th Jul 20159:12 amRNSHolding(s) in Company
7th Jul 20154:21 pmRNSHolding(s) in Company
6th Jul 20153:59 pmRNSHolding(s) in Company
2nd Jul 20157:00 amRNSTrading Update
22nd Jun 20153:51 pmRNSHolding(s) in Company
20th May 20158:57 amRNSHolding(s) in Company
14th May 201510:02 amRNSDirector/PDMR Shareholding
30th Apr 201512:53 pmRNSResult of AGM
30th Apr 201512:46 pmRNSDirectorate Change
30th Apr 20157:00 amRNSQuarter 1 Trading Update
27th Apr 201510:36 amRNSDirectorate Change
21st Apr 20155:16 pmRNSHolding(s) in Company
1st Apr 20158:15 amRNSDirectorate Change
31st Mar 20159:25 amRNSAnnual Financial Report
30th Mar 201510:13 amRNSHolding(s) in Company
27th Mar 201512:53 pmRNSDirector/PDMR Shareholding
23rd Mar 20157:00 amRNSDirectorate Change
19th Mar 201511:53 amRNSDirector Declaration
18th Mar 20154:47 pmRNSDirector/PDMR Shareholding
13th Mar 20159:35 amRNSHolding(s) in Company
27th Feb 20153:06 pmRNSDirector/PDMR Shareholding
27th Feb 20153:05 pmRNSDirector/PDMR Shareholding
26th Feb 20157:01 amRNSFinal Results
20th Jan 20151:58 pmRNSNotice of Results
16th Jan 20157:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.